NOVO VENTURES CO-LEADS US$83M SERIES C FINANCING IN LAVA THERAPEUTICS
Novo Ventures, the ventures arm of Novo Holdings, today announced that it … Continue reading “NOVO VENTURES CO-LEADS US$83M SERIES C FINANCING IN LAVA THERAPEUTICS”
Novo Ventures, the ventures arm of Novo Holdings, today announced that it … Continue reading “NOVO VENTURES CO-LEADS US$83M SERIES C FINANCING IN LAVA THERAPEUTICS”
ALAMEDA, Calif. and BASEL, Switzerland – September 8, 2020 – Exelixis, Inc. (Nasdaq: … Continue reading “Exelixis and NBE-Therapeutics Enter into Exclusive Collaboration and License Option Agreement to Discover and Develop Novel Antibody-Drug Conjugates for the Treatment of Cancer”
SOUTH SAN FRANCISCO, Calif. (August 13, 2020) Mission Bio, Inc., the pioneer in high-throughput … Continue reading “Mission Bio Raises $70M in Series C Funding Led by Novo Holdings to Accelerate Development of Cancer Therapies with Single-cell Multi-omics”
G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, and Bionical Emas, a … Continue reading “G1 Therapeutics, Inc. and Bionical Emas Launch Expanded Access Program for Trilaciclib in Small Cell Lung Cancer in the United States”
Novo Holding A/S, a world-leading life science investor with a focus on … Continue reading “Novo Holdings bolsters Principal Investments team with key US appointments”
As Head of Principal Investments, Christoffer Søderberg will be overall responsible for … Continue reading “Novo Holdings appoints Christoffer Søderberg as Head of Principal Investments”
Funding enables accelerated development of fermentation-derived next-generation food colorants Flagship product targeting … Continue reading “Novo Holdings leads seed round in Chromologics”
Amsterdam, The Netherlands, August 29, 2020 – Kiadis Pharma N.V. (“Kiadis” or … Continue reading “Kiadis announces new data demonstrating FC21-NK cells were well tolerated and showed encouraging signs of antitumor and suspected antimicrobial activity in 13 patients with relapsed/refractory acute myeloid leukemia (R/R AML)”
F2G Ltd, a UK- and Austria-based biotech developing novel therapies for life-threatening … Continue reading “F2G Closes US$60.8 Million Financing to fund late stage development of novel mechanism antifungal agent”
Novo Ventures, the ventures arm of Novo Holdings, today announces that its … Continue reading “Novo Ventures Portfolio Company F2G Closes US$60.8 Million Financing”
Industry Veteran and Immune Oncologist with over 35 years’ Experience in the … Continue reading “NBE-Therapeutics Appoints Erich Schlick as Chairman of the Board of Directors”
BaseLaunch, the Basel Area-based biotech venture accelerator and incubator, today announces that CSL … Continue reading “CSL Behring to become latest partner in BaseLaunch Phase II”
Josep Tabernero joins SAB and Julian Blagg elevated to SAB Chair Martin … Continue reading “NeoPhore Strengthens Scientific Leadership Team”
20 Years’ Industry Experience Managing Biotech Companies in US and Europe Aim … Continue reading “NBE-Therapeutics Appoints Bertrand Damour as Chief Executive Officer”
EUR23M Series A Financing to Advance Lead Novel Llama-derived Antibody into Clinical … Continue reading “ExeVir Bio to Accelerate Development of New Treatment Conferring Broad Protection Against Covid-19”
Fund+ strengthens portfolio with medical device company developing a novel ‘invisible’ sensor … Continue reading “Fund+ Leads EUR38 Million Series B Financing in Indigo Diabetes NV”
Sydney, Australia and Los Angeles, California 21 July 2020 – Clarity Pharmaceuticals, … Continue reading “Clarity Pharmaceuticals and ImaginAb to collaborate on new cancer targets”
LONDON and RALEIGH, N.C., July 17, 2020 (GLOBE NEWSWIRE) — Verona Pharma … Continue reading “Verona Pharma Raises $200 Million in Oversubscribed Private Placement and Subscription”
BaseLaunch, the Basel Area-based biotech venture accelerator and incubator, today announces that … Continue reading “Bridge Biotherapeutics becomes BaseLaunch’s first Asia Pacific partner”
For more information about Optimum Strategic Communications, please get in touch
We'd love to hear from you...
GET IN TOUCH
© Copyright 2020 Optimum Strategic Communications All rights reserved.
Warnford Court
29 Throgmorton Street
London
EC2N 2AT
Tel: +44 (0)203 950 9144
Email: contact@optimumcomms.com
